These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16548790)

  • 1. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
    Kemp SF; Thrailkill KM
    Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mecasermin rinfabate.
    Kemp SF; Fowlkes JL; Thrailkill KM
    Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mecasermin rinfabate.
    Kemp SF
    Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SomatoKine: is there a use in treating growth disorders?
    Kemp SF; Thrailkill KM
    Curr Opin Investig Drugs; 2005 Apr; 6(4):373-7. PubMed ID: 15898344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant IGF-I: Past, present and future.
    Bright GM
    Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-I alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth.
    Ekström K; Carlsson-Skwirut C; Ritzén EM; Bang P
    Horm Res Paediatr; 2011; 76(5):355-66. PubMed ID: 21968387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
    Williams RM; McDonald A; O'Savage M; Dunger DB
    Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatomedin-1 binding protein-3: insulin-like growth factor-1 binding protein-3, insulin-like growth factor-1 carrier protein.
    BioDrugs; 2003; 17(5):375-9. PubMed ID: 14498768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGFs and IGFBPs in GH insensitivity.
    Savage MO; Blair JC; Jorge AJ; Street ME; Ranke MB; Camacho-Hübner C
    Endocr Dev; 2005; 9():100-106. PubMed ID: 15879692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.
    Gorbenko del Blanco D; de Graaff LC; Visser TJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2012 May; 76(5):706-12. PubMed ID: 22117696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome.
    Burren CP; Woods KA; Rose SJ; Tauber M; Price DA; Heinrich U; Gilli G; Razzaghy-Azar M; Al-Ashwal A; Crock PA; Rochiccioli P; Yordam N; Ranke MB; Chatelain PG; Preece MA; Rosenfeld RG; Savage MO
    Horm Res; 2001; 55(3):125-30. PubMed ID: 11549873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of the insulin-like growth factors.
    Savage MO; Camacho-Hübner C; Dunger DB
    Growth Horm IGF Res; 2004 Aug; 14(4):301-8. PubMed ID: 15231299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.
    Erol N; Yıldız M; Güven A; Yıldırım A
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):675-679. PubMed ID: 29750649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency.
    Backeljauw P
    Growth Horm IGF Res; 2020 Apr; 51():22-26. PubMed ID: 31982729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.